199
report
Demographic Reporting and Mix in Clinical Trials
Clinical trial enrollment can vary based on demographics. Cancer drug trials, for example, have bee
n shown to skew disproportionately toward young, White, male participants.
+ Read More
report
Innovative Finance Models for Global Early Warning Systems for Pandemics
Despite lessons learned from COVID-19 and other outbreaks, the world remains ill-prepared for the n
ext pandemic.
+ Read More
report
Protecting the Progress for Biomedical Innovation: A Post-Pandemic Scorecard
Since early in the COVID-19 pandemic, FasterCures has been committed to capturing lessons learned a
nd opportunities to improve the biomedical research ecosystem.
+ Read More
report
Corporate Philanthropy: Emerging Strategies for Lasting Impact
Corporate philanthropy is in transition. External trends and heightened stakeholder expectations ha
ve placed new pressures on the corporate sector.
+ Read More
report
Request for Proposals: Kissick Family Foundation Frontotemporal Dementia Grant Program
The Kissick Family Foundation, with guidance from MI Philanthropy’s Science and Health team, is rel
easing its first Request for Proposals (RFP) to fund research that accelerates basic and fundamental discoveries for sporadic FTD.
+ Read More
report
Frontotemporal Dementia: A Giving Smarter Guide
Frontotemporal dementia (FTD) refers to a family of neurodegenerative conditions that cause changes
in behavior, mood, executive function, language, memory, and motor function.
+ Read More
report
Key Trends in Health at Milken Institute Global Conference 2024
The 27th Milken Institute Global Conference delved into the theme “Shaping a Shared Future.” Throug
hout the four-day event, MI Health launched key initiatives and highlighted ongoing
+ Read More
report
Catalyzing Action for Pharmacist-Provided Food Is Medicine Care
Pharmacies are cornerstones of local health care, providing access to immunizations, screenings, tr
eatments, and health-related social needs across communities.
+ Read More
report
Distance as an Obstacle to Clinical Trial Access: Who Is Affected and Why It Matters
Access to clinical trials is valuable for patients as it provides the possibility to obtain novel t
reatments that are not yet commercially available.
+ Read More
panel
(Parent Session Title Will Not Publish to Web)
panel